AR032912A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
AR032912A1
AR032912A1 ARP020100712A ARP020100712A AR032912A1 AR 032912 A1 AR032912 A1 AR 032912A1 AR P020100712 A ARP020100712 A AR P020100712A AR P020100712 A ARP020100712 A AR P020100712A AR 032912 A1 AR032912 A1 AR 032912A1
Authority
AR
Argentina
Prior art keywords
bicalutamide
pharmaceutical formulation
refers
enteric polymer
formulation
Prior art date
Application number
ARP020100712A
Other languages
English (en)
Inventor
Julie Cahill
Nicola Bateman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104749A external-priority patent/GB2372444A/en
Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR032912A1 publication Critical patent/AR032912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulacion farmacéutica que comprende bicalutamida y un polímero entérico que tiene un pKa de 3 a 6. La presente también se refiere a una dosis farmacéutica diaria de bicalutamida proporcionada por dicha formulacion. Además, la presente se refiere al uso de dicho polímero entérico en dispersion solida con bicalutamida para aumentar la biodisponibilidad de la bicalutamida; para reducir la variabilidad entre pacientes en concentraciones de plasma de bicalutamida; o para tratar y/o reducir el riesgo de cáncer de prostata en un paciente.
ARP020100712A 2001-02-27 2002-02-27 Formulacion farmaceutica AR032912A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104749A GB2372444A (en) 2001-02-27 2001-02-27 A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv) 2001-07-19 2001-07-19 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR032912A1 true AR032912A1 (es) 2003-12-03

Family

ID=26245766

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100712A AR032912A1 (es) 2001-02-27 2002-02-27 Formulacion farmaceutica

Country Status (22)

Country Link
US (1) US20040067257A1 (es)
EP (1) EP1368001B1 (es)
JP (2) JP3548566B2 (es)
KR (1) KR20030077042A (es)
CN (1) CN1503662A (es)
AR (1) AR032912A1 (es)
AT (1) ATE307571T1 (es)
CA (1) CA2439366A1 (es)
CZ (1) CZ20032225A3 (es)
DE (1) DE60206889T2 (es)
EE (1) EE200300416A (es)
HU (1) HUP0302847A3 (es)
IL (1) IL157389A0 (es)
IS (1) IS6915A (es)
MX (1) MXPA03007641A (es)
NO (1) NO20033785L (es)
NZ (1) NZ527532A (es)
PL (1) PL365746A1 (es)
RU (1) RU2003128971A (es)
SK (1) SK10722003A3 (es)
UY (1) UY27186A1 (es)
WO (1) WO2002067893A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
WO2005074991A1 (ja) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi 抗腫瘍剤
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
CN101128195A (zh) * 2005-02-23 2008-02-20 阿斯利康(瑞典)有限公司 用于递送增加的稳态血浆水平的比卡鲁胺
US8293274B2 (en) * 2005-04-06 2012-10-23 Kabushiki Kaisha Sangi Intestinal absorptive anti-tumor agent
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2191830A4 (en) 2007-09-21 2011-11-23 Shionogi & Co SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
JP2011503048A (ja) * 2007-11-08 2011-01-27 グラクソ グループ リミテッド 医薬製剤
HUE027598T2 (en) * 2009-04-03 2016-10-28 Hoffmann La Roche Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
US9545407B2 (en) * 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
EA201791222A1 (ru) 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
WO2020210723A1 (en) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
EP4100075A4 (en) 2020-03-20 2024-01-31 The Regents of University of California IMPLANTABLE DRUG RELEASE DEVICES FOR LOCALIZED DRUG RELEASE
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CA2443040A1 (en) * 2001-04-02 2002-10-17 Nicola Frances Bateman Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Also Published As

Publication number Publication date
ATE307571T1 (de) 2005-11-15
WO2002067893A3 (en) 2003-01-16
EE200300416A (et) 2003-12-15
DE60206889D1 (de) 2005-12-01
RU2003128971A (ru) 2005-03-10
PL365746A1 (en) 2005-01-10
JP2004143185A (ja) 2004-05-20
CN1503662A (zh) 2004-06-09
NZ527532A (en) 2004-12-24
KR20030077042A (ko) 2003-09-29
WO2002067893A2 (en) 2002-09-06
DE60206889T2 (de) 2006-07-27
JP3548566B2 (ja) 2004-07-28
UY27186A1 (es) 2002-09-30
SK10722003A3 (sk) 2004-02-03
US20040067257A1 (en) 2004-04-08
HUP0302847A3 (en) 2005-05-30
MXPA03007641A (es) 2003-12-04
NO20033785D0 (no) 2003-08-26
CA2439366A1 (en) 2002-09-06
JP2004521918A (ja) 2004-07-22
EP1368001A2 (en) 2003-12-10
IL157389A0 (en) 2004-05-12
IS6915A (is) 2003-08-15
CZ20032225A3 (cs) 2003-11-12
HUP0302847A2 (hu) 2003-12-29
NO20033785L (no) 2003-10-24
EP1368001B1 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
UY27186A1 (es) Formulación farmacéutica
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
AR090677A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
AR032293A1 (es) Estuche farmaceutico
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
AR027355A1 (es) Acidos tiazolidincarboxilicos
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
AR036877A1 (es) Formulacion farmaceutica
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
AR037390A1 (es) Formulacion farmaceutica
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BR0012735A (pt) Preparação solida, e, processo para produzir preparações
PL368686A1 (en) Novel aminobenzoephenones
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839

Legal Events

Date Code Title Description
FA Abandonment or withdrawal